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SUMMARY 29 
Sphingosine kinase 1 (SphK1) is a lipid kinase with important roles including regulation of cell 30 
survival.  We have previously shown reduced SphK1 activity in cells with an established dengue virus 31 
type-2 (DENV-2) infection.  In this study we have examined the effect of alterations in SphK1 32 
activity on DENV-2 replication and cell death and determined the mechanisms of the reduction in 33 
SphK1 activity.  Chemical inhibition or overexpression of SphK1 after established DENV-2 infection 34 
had no effect on infectious DENV-2 production, although inhibition of SphK1 resulted in enhanced 35 
DENV-2-induced cell death.  Reduced SphK1 activity was observed in multiple cell types, regardless 36 
of the ability of DENV-2 infection to be cytopathic, and was mediated by a post-translational 37 
mechanism.  Unlike bovine viral diarrhoea virus (BVDV), where SphK1 activity is decreased by the 38 
NS3 protein, SphK1 activity was not affected by DENV-2 NS3 but instead was reduced by expression 39 
of the terminal 396 bases of the 3’ untranslated region (UTR) of DENV-2 RNA.  We have previously 40 
shown that eukaryotic elongation factor 1A (eEF1A) is a direct activator of SphK1 and here DENV-2 41 
RNA co-localised and co-precipitated with eEF1A from infected cells.  We propose that the reduction 42 
in SphK1 activity late in DENV-2-infected cells is a consequence of DENV-2 out-competing SphK1 43 
for eEF1A binding and hijacking cellular eEF1A for its own replication strategy rather than a specific 44 
host or virus-induced change in SphK1 to modulate viral replication.  Nonetheless reduced SphK1 45 
activity may have important consequences for survival or death of the infected cell. 46 
47 
INTRODUCTION 48 
Dengue virus (DENV) is a flavivirus of the Flaviviridae family that is responsible for a significant 49 
mosquito borne infection in humans leading to mild fever (dengue fever; DF) or more severe dengue 50 
haemorrhagic fever (DHF) and dengue shock syndrome (DSS), more recently termed dengue or 51 
severe dengue (Clyde et al., 2006; Martina et al., 2009; Simmons et al., 2012).  The more severe 52 
forms of disease are characterised by increased vascular leakage that is proposed to be induced by 53 
pathogenic host responses including elevated release of inflammatory mediators (Halstead, 2007; 54 
Rothman, 2011; Simmons et al., 2012).  One important inflammatory and vasoactive factor is TNF-α, 55 
which is released at high levels from DENV-infected cells (Carr et al., 2003; Chen & Wang, 2002) 56 
and associated with DENV-induced haemorrhage in human studies (Hober et al., 1993) and mouse 57 
models of infection (Chen et al., 2007; Shresta et al., 2006; Yen et al., 2008).  We have previously 58 
shown altered TNF-α responses, with induction of cell death and inability to activate pro-survival 59 
NFκB-driven signals in DENV-2-infected cells (Wati et al., 2007; Wati et al., 2011).  The timing of 60 
these altered TNF-α responses co-incides with reduced activity of sphingosine kinase1 (SphK1) in 61 
these cells (Wati et al., 2011).  SphK1 is an important mediator of TNF-α stimulated NFκB responses 62 
(Alvarez et al., 2010; Li & Lin, 2008; Xia et al., 2002) via the generation of the bioactive lipid 63 
mediator, sphingosine-1-phosphate (S1P) (Leclercq & Pitson, 2006; Pitson, 2011).  S1P is a pro-64 
survival and immunomodulatory factor that can act as an intracellular signalling molecule or be 65 
secreted from the cell and act extracellularly via a family of five S1P-specific G-protein coupled 66 
receptors (S1P1-5) (Hannun & Obeid, 2008; Maceyka et al., 2009; Takabe et al., 2008).  The activity 67 
of SphK1 is tightly regulated within cells by mechanisms, including 68 
phosphorylation/dephosphorylation (Barr et al., 2008; Pitman et al., 2011; Pitman & Pitson, 2010; 69 
Pitson et al., 2003), plasma membrane localisation (Jarman et al., 2010; Wattenberg et al., 2006), and 70 
interaction with cellular activators such as eukaryotic elongation factor 1A (eEF1A) (Leclercq et al., 71 
2011; Leclercq et al., 2008).  This latter interaction results in increased cellular SphK1 activity 72 
(Leclercq et al., 2011; Leclercq et al., 2008). 73 
 74 
Important roles of SphK1 and S1P in viral infections are beginning to emerge (Carr et al., 2013).  75 
Studies have shown that SphK1 activity is enhanced in respiratory syncytial virus (RSV) (Monick et 76 
al., 2004) and human cytomegalovirus (HCMV) infected cells (Machesky et al., 2008).  RSV 77 
infection activates AKT and ERK which leads to increased SphK1 activity, and this early RSV-78 
induced pro-survival stimulus prevents pre-mature viral induced cell death (Monick et al., 2004).  79 
Similarly, activation of SphK1 is also proposed to prevent viral-induced cell death and allow 80 
persistence of HCMV (Machesky et al., 2008).  Additionally, influenza virus infection was enhanced 81 
by overexpression of SphK1, but reduced when S1P lyase (SPL), the enzyme that degrades S1P, was 82 
overexpressed (Seo et al., 2010).  Together, this data suggests an important role for enhanced host cell 83 
SphK1 and S1P in viral infection and persistence.  In contrast, SphK1 is inhibited in bovine viral 84 
diarrhoea virus (BVDV) infected cells via direct binding and inhibition by the BVDV NS3 protein, 85 
with this inhibition necessary for BVDV-induced cytopathic effect (CPE) (Yamane et al., 2009).  86 
Notably, BVDV is a pestivirus of the Flaviviridae family and related to the flavivirus DENV, where 87 
we have reported a similar reduction in SphK1 activity late in infection (Wati et al., 2011). 88 
 89 
In this study we have investigated the biological effects and molecular mechanisms mediating the 90 
later reduced SphK1 activity in DENV-2 infected cells.  Although changes in SphK1 activity had no 91 
effect on DENV-2 replication, lowering SphK1 activity enhanced DENV-2-induced cell death/cell 92 
proliferation.  The reduction in SphK1 activity late in DENV-2 infected cells occurs via a post-93 
translational effect that can be mediated by the DENV-2 3’UTR.  The DENV-2 3’UTR is known to 94 
interact with the host cell factor eEF1A and we propose that the 3’UTR sequesters this constitutive 95 
SphK1-activating protein away from SphK1, thereby reducing cellular SphK1 activity.  Thus, this 96 
study provides essential understanding of how DENV-2 co-opts the host cell and can influence 97 
cellular factors, such as SphK1that can have important implications for altered function of infected 98 
cells. 99 
 100 
 101 
 102 
RESULTS 103 
Alterations in SphK1 activity do not affect DENV-2 infection.  To examine the biological effect that 104 
changes in SphK1 activity late in infection (the time where we previously observed a reduction in 105 
SphK1 activity) have on DENV-infection, we performed DENV-2 infection in cells with over-106 
expression or chemical reduction in SphK1 activity.  HEK-293 cells with doxycycline (DOX)-107 
inducible expression of SphK1, a catalytically inactive version of this enzyme, SphK1G82D, or vector 108 
control were utilised to provide controllable level and timing of SphK1 induction (Loveridge et al., 109 
2010; Pham et al., 2008).  DOX was added immediately post DENV-2 infection and at 24h pi cell 110 
lysates were collected for quantitation of SphK1 activity.  DOX treatment induced a substantial 111 
increase in SphK1 activity in both mock and DENV-infected cells Fig 1(a) although, like the effect of 112 
DENV-2 infection on endogenous SphK1, SphK1 activity tended to be lower in DOX treated DENV-113 
2 infected cells.  Despite this, no difference in infectious DENV-2 production was observed between 114 
cells with or without elevated SphK1 activity Fig 1(b).  A visual CPE was induced by DENV-2 115 
infection at 48-72h pi, as previously described (Wati et al., 2011) which presented as rounding up of 116 
cells and detaching from the plate representing cell death.  This CPE was not prevented by 117 
overexpression of SphK1 (data not shown).  We also assessed the effect of expression of the 118 
catalytically inactive SphK1G82D, which we have previously shown acts as a dominant negative 119 
version of SphK1 that prevents SphK1 activation (Pitson et al., 2000).  Again, although there was 120 
substantial induction of SphK1G82D protein, Fig 1(c), there was no significant effect on infectious 121 
DENV-2 production, Fig 1(d). 122 
 123 
Conversely, the reduction in SphK1 activity seen normally in DENV-2 infected cells may be required 124 
to facilitate infection and thus we assessed if a further chemical reduction in SphK1 activity late in 125 
infection could enhance DENV-2 infection.  HEK-293 cells were DENV-2 -infected then treated with 126 
the SphK1 inhibitor SKi (Loveridge et al., 2010).  At 30 h pi cells treated with SKi had significantly 127 
lower SphK1 activity that was maintained up to 48 h pi, Fig 2(a). SKi treatment, however, had no 128 
effect on production of infectious DENV-2, Fig 2(b). Similarly, DENV-2 infection followed by SKi 129 
treatment of MDM did not affect production of infectious DENV-2 at 48h pi, which represents the 130 
peak of viremia in this infection model, Fig 2(c). 131 
 132 
Notably, the visual CPE induced by DENV-2 infection of HEK-293 cells at 48-72h pi was further 133 
exacerbated by treatment with SKi and this was quantitated by vital dye staining.  HEK-293 cells 134 
were DENV-2 infected and treated with SKi.  Cell lysates were collected from mock and DENV 135 
infected cells and SphK1 activity assayed from 24-72h pi.  DMSO treatment of cells did not affect 136 
SphK1 activity in mock-infected cells (data not shown) but we observed the DENV-2-induced 137 
reduction in SphK1 activity, as described previously (Wati et al., 2011), Fig 3(a).  SKi treatment of 138 
mock or DENV-2-infected cells reduced SphK1 activity with a significantly greater reduction in 139 
SphK1 activity in DENV-2 compared with mock-infected cells that was maintained up to 72 h pi, Fig 140 
3(b).  Consistent with results in Fig 2, SKi treatment did not significantly affect production of DENV-141 
2 virus (data not shown).  Cell viability was then quantitated by crystal violet staining at 24-72h pi.  142 
As expected, DENV-2 infection alone reduced cell viability by 48h pi, Fig 3(c).  Although SKi 143 
treatment alone also reduced the viability of mock-infected cells at 48h pi, SKi had a greater effect in 144 
reducing the viability of DENV-2 infected cells at both 48h and 72h pi, Fig 3(c).  The results of the 145 
viability staining may reflect both cell proliferation rate and cell death, but notably dead cells were 146 
visually observed with both SKi treatment and DENV-2 infection. 147 
 148 
Based on the data above, SphK1 itself shows no ability, in the context of physiologically relevant 149 
levels of SphK1 protein, to regulate DENV-2 infection but reduced levels can enhance the DENV-2 150 
induced CPE in HEK-293 cells.  Further, reduced SphK1 activity has been linked to induction of a 151 
CPE in BVDV (Yamane et al., 2009) and RSV infections (Monick et al., 2004).  To examine if this is 152 
also the case in DENV-2 infection, SphK1 activity was assessed in cells that show visual cell death 153 
and CPE upon DENV-2 infection (BHK-21, HEK-293 and C6/36) and where virus infection is non-154 
cytopathic (K562, primary monocyte-derived macrophages [MDM]).  Cells were mock or DENV-2-155 
infected and prior to the onset of visual CPE in BHK-21, HEK-293 and C6/36 cells  or at high level 156 
infectious virus production (K562, MDM), cells were lysed and SphK1 activity quantitated.  Results 157 
show a significant reduction in SphK1 activity in all cell types analysed, irrespective of the ability of 158 
DENV-2 to subsequently induce a CPE, Fig 4, indicating that the DENV-2-induced reduction in 159 
SphK1 activity occurs in many different cell types but does not necessarily lead to DENV-2-induced 160 
cell death. 161 
 162 
Reduced SphK1 activity in DENV-2 infected cells is mediated by post-translational mechanisms.  We 163 
next determined the mechanism by which SphK1 activity is reduced in DENV-2 infected cells. We 164 
used techniques for analysis of gross changes in HEK-293 cells, where the majority of cells are 165 
infected (western blot and total RNA analysis), and techniques to look at individual cells in MDM, 166 
where only approximately 10% of the cells become DENV-infected (immunostaining and 167 
microscopy). This has the advantages of direct comparison of DENV negative and positive cells from 168 
the same cell population and also potentially demonstrating any affects in uninfected bystander cells.  169 
Western blot of cell lysates were taken at 30h pi, the time point in HEK-293 cells where reduced 170 
SphK1 activity becomes significant but prior to the onset of CPE.  Results showed comparable levels 171 
of total SphK1 protein from DENV-2 and mock infected HEK-293 cells, Fig 5(a).  Similarly, 172 
immunostaining for SphK1 did not differ between mock and DENV-2 infected primary MDM, Fig 173 
5(b) or between DENV-2 antigen negative and positive cells of the DENV-infected population, Fig 174 
5(b). The validity of our ability to detect differences in SphK1 protein levels using western blot or 175 
immunostaining has been demonstrated (Fig S1).  We next assessed the effect of DENV-2 infection 176 
on SphK1 steady state mRNA levels.  Total RNA was extracted from HEK-293 cells at 30h pi and 177 
SphK1 mRNA levels examined by quantitative RT-PCR (qPCR).  Results showed no difference in 178 
SphK1 mRNA levels in mock or DENV-2-infected cells, Fig 5(c).  We have recently reported the 179 
presence of trans-acting SphK1 inhibitory or activating factors in lysates from cells (Chan & Pitson, 180 
2013) and we assessed the presence of SphK1 inhibitory or enhancing activity in DENV-2 infected 181 
compared with mock-infected cell lysates using an in vitro activity assay with recombinant SphK1.  182 
Notably, the activity of recombinant human SphK1 (rSphK1) was selectively enhanced by incubation 183 
with lysates from mock, but not DENV-2-infected cells, Fig 5(d).  Importantly, the contribution of 184 
SphK1 activity in the lysates was insignificant (less than 1%) compared to the activity of rSphK1 in 185 
this system.  Thus, these results suggest post-translational effects on SphK1 either via the presence of 186 
SphK1-inhibitory factors or loss of SphK1-activating factors in the lysates from DENV-2-infected 187 
cells. 188 
 189 
DENV-2-induced reduction in SphK1 activity can be mediated by the DENV-2 3’UTR that interacts 190 
with the SphK1 activator, eEF1A.  Since the NS3 protease/helicase from the related Flaviviridae 191 
BVDV has been previously reported to bind and inhibit SphK1 activity (Yamane et al., 2009) we next 192 
assessed if expression of the NS3 protease/helicase from DENV-2 could similarly inhibit SphK1 193 
activity.  HEK-293 cells were transfected with vectors encoding DENV NS3-GFP fusion protein or 194 
control GFP, and at 24h post transfection expression confirmed by visualisation of GFP (58 ± 4 % and 195 
63 ± 5 % of cells GFP positive, respectively), cells harvested, lysed and assayed for SphK1 activity.  196 
This time point post transfection was chosen since it represented good transgene expression without 197 
the later observed CPE, possibly due to high level GFP expression, which has the potential to 198 
influence SphK1 activity.  Somewhat surprisingly, and in contrast to the situation in BVDV, no 199 
significant difference in SphK1 activity was observed between GFP or GFP-DENV-NS3 expressing 200 
cells, Fig 6(a), suggesting DENV-2 NS3 alone does not affect SphK1 activity in cells. 201 
 202 
It is well established that the flavivirus 3’UTR can bind via the 3’UTR stem loop (SL) structure to 203 
eEF1A (Blackwell & Brinton, 1997; Davis et al., 2007).  eEF1A is a highly expressed cellular protein 204 
which we have previously shown also binds and enhances the catalytic activity of SphK1 and acts as a 205 
constitutive endogenous activator of this enzyme (Leclercq et al., 2008).  We thus assessed the ability 206 
of the DENV-2 3’UTR to inhibit eEF1A-stimulated SphK1 activity.  The terminal 396 bases of the 207 
DENV-2 3’UTR was cloned downstream of GFP to create a construct that would express GFP mRNA 208 
as a 3’UTR RNA fusion and also produce GFP as a visual marker of transfection.  HEK-293 cells 209 
were transfected with GFP control or GFP-3’UTR RNA expressing constructs.  Transfection and 210 
expression of GFP protein was confirmed by fluorescence microscopy (63 ± 5 % and 70 ± 4 % of 211 
cells GFP positive, respectively).  The presence of DENV-2 3’UTR RNA was also quantitated by 212 
qRT-PCR.  Results demonstrated comparable levels of 3’UTR RNA in transfected cells to that seen in 213 
DENV-2-infected HEK-293 cells (10±7, 2.8±0.6 and 5.6±1.8 ng/106 cells for transfected GFP-3’UTR 214 
and DENV-2 HEK-293 cells at 24 and 48h pi, respectively).  Lysis of transfected cells and analysis of 215 
SphK1 activity showed a significant reduction in SphK1 activity in GFP-3’UTR, compared with GFP 216 
expressing cells, Fig 6(b).  We rationalised that a reduction in SphK1 activity mediated by the 3’UTR 217 
should be specifically observed late in viral infection when levels of positive and negative strand 218 
DENV-2 RNA increase and higher levels of a small flavivirusRNA (sfRNA) containing the 3’UTR 219 
are present (Funk et al., 2010).  We thus analysed the time course of SphK1 activity during DENV-2 220 
infection.  As predicted, a significant DENV-2-induced reduction in SphK1 activity was specifically 221 
observed late in infection, Fig 7(a) which co-incided with high levels of infectious virus release, Fig 222 
7(b) and levels of 3’UTR RNA, Fig 7(c). 223 
 224 
eEF1A has been shown to co-localise with DENV NS3/NS5 in potential replication complexes and is 225 
required for DENV replication (Davis et al., 2007).  We next investigated changes in eEF1A in 226 
DENV-2-infected cells at the time we observe reduced SphK1 activity.  Western blot analysis of cell 227 
lysates taken at 30h pi from DENV-2 and mock-infected HEK-293 showed no difference in the levels 228 
of eEF1A protein, Fig 8(a).  Further, DENV-2 or mock-infected 293-T cells were fixed and 229 
immunostained for eEF1A in combination with dsRNA, Fig 8(b).  The staining for eEF1A is diffuse 230 
in mock-infected cells and similar intensity in DENV-2 infected cells, Fig 8(b). A more punctate 231 
eEF1A staining was observed in DENV-2 infected cells with regions of co-localisation of eEF1A with 232 
dsRNA, Fig 8(b).  The physical association of eEF1A and DENV-2 RNA was then assessed.  Lysates 233 
from DENV-2 infected cells were incubated with or without an eEF1A antibody, precipitated with 234 
protein A-sepharose and co-precipitation of DENV-2 RNA assessed by qRT-PCR.  Results showed 235 
co-precipitation of DENV-2 RNA with an eEF1A antibody, confirming the interaction of these two 236 
factors, Fig 8(c), and extending prior studies showing an association of eEF1A with the NS3 and NS5 237 
proteins of DENV and WNV (Davis et al., 2007) and RNA of WNV (Blackwell & Brinton, 1997). 238 
 239 
DISCUSSION 240 
SphK1 is a lipid kinase recognised as a central and important mediator of pro-survival and cell death 241 
signals (Leclercq & Pitson, 2006; Pitson, 2011), but few studies have assessed SphK1 activity in 242 
virally infected cells (Carr et al., 2013).  SphK1 activity is increased following HCMV and RSV 243 
infection (Machesky et al., 2008; Monick et al., 2004), but reduced late in infection with the 244 
Flaviviridae, DENV-2 (Wati et al., 2011) and BVDV (Yamane et al., 2009).  Interestingly, SphK2 245 
gene expression is reduced in cells expressing proteins of the Flaviviridae HCV (Vandermeeren et al., 246 
2008).  The study herein has focused on the biological effect and mechanisms of the observed 247 
reduction in SphK1 activity late in infection in DENV-2 infected cells. 248 
 249 
Our results show that overexpression or further inhibition of SphK1 activity after DENV-2 infection 250 
has no effect on DENV-2 infection and suggests that once an infection is established, the SphK1 251 
enzyme itself does not regulate DENV-2 replication and virus production.  This contrasts to BVDV 252 
infection where BVDV RNA production was increased following SKi treatment of infected cells 253 
(Yamane et al., 2009).  Importantly, the functional changes that alterations in SphK1 activity may 254 
impart to the infected cell may be significant, particularly in relation to cell death.  Virus-mediated 255 
inhibition of SphK1 activity during BVDV infection is related to the ability of different BVDV 256 
isolates to induce CPE in vitro, with SphK1 overexpression blocking virus induced CPE (Yamane et 257 
al., 2009).  Chemical inhibition of SphK1 activity also increased RSV induced cell death (Monick et 258 
al., 2004).  Conversely, overexpression of SPL, the S1P degrading enzyme, inhibited influenza virus-259 
induced CPE (Seo et al., 2010).  In our study the reduction in SphK1 activity in different DENV-2-260 
infected cell types is not linked to the ability of DENV-2 to induce a CPE and further, up-regulating 261 
SphK1 did not counteract the DENV-2 induced CPE.  This suggests that additional cell death 262 
pathways independent or downstream of SphK1 actions are important in illiciting DENV-2 induced 263 
cell killing.  In contrast, SKi treatment has a greater effect on cellular SphK1 activity and cell 264 
death/proliferation rate in DENV-2 compared with mock-infected cells and suggests that during 265 
DENV-2 infection, the further reduction in SphK1 activity can tip the balance towards cell death, 266 
potentially in response to additional cell death triggers.  For example, we have previously reported 267 
that TNF-α responses are altered in DENV-2 infected cells with reduced ability of TNF-α to degrade 268 
IkB-α and activate NFκB and induction of cell death (Wati et al., 2011).  These responses are co-269 
incident with the DENV-2-induced reduction in SphK1 activity which may be a significant 270 
contributor to these virus-induced changes in TNF-α responses. 271 
 272 
Interestingly, changes in SphK1 activity can influence the levels of the substrates/substrate precursors 273 
for SphK1, such as sphingosine, ceramide, sphingomyelin and other components of the sphingolipid 274 
biosynthetic pathway.  Indeed, changes in the lipidome during virus infections is a new area of active 275 
interest.  Studies have shown increased levels of ceramide and sphingomyelin in HCV infected 276 
infected cells (Diamond et al., 2010). Sphingolipids have also been suggested to promote HCV 277 
replication, potentially by direct binding of NS5B to sphingomyelin in detergent resistant membranes 278 
(Hirata et al., 2012) and SphK1 gene expression is reportedly increased in HCV susceptible Huh7.5.1 279 
cells compared to HCV resistant Huh7 cell lines (MacPherson et al., 2011).  Similarly, increased 280 
levels of ceramide and sphingomyelin have been observed in DENV-infected mosquito cells (Perera 281 
et al., 2012).  Our observed changes in SphK1 activity in DENV-infected cells may be an important 282 
contributor to these changes in cellular sphingolipid profiles.  Although not directly related to 283 
sphingolipid biosynthesis, DENV infection has been demonstrated to alter lipid droplets (Heaton & 284 
Randall, 2011) and stimulate fatty acid synthetase (FASN) enzyme activity (Heaton et al., 2010), 285 
highlighting the importance of lipid remodelling during DENV infection with these changes being a 286 
clear area of future interest. 287 
 288 
In this study we have defined a novel mechanism by which DENV-2 can influence cellular enzymatic 289 
functions.  We observed unchanged SphK1 mRNA and protein levels and the ability of lysates from 290 
mock but not DENV-2 infected cells to activate rSphK1 in vitro, indicating a post-translational 291 
mechanism of DENV-2-inhibition of SphK1 activity.  Similarly in BVDV-infected cells (Yamane et 292 
al., 2009), the reduction in SphK1 activity is not associated with a change in SphK1mRNA.  This 293 
contrasts to RSV and HCMV infections, where the virus-induced increase in SphK1 activity is 294 
accompanied by an increase in SphK1 mRNA.  In BVDV infection, inhibition of SphK1 activity is 295 
mediated by direct binding of BVDV NS3 protease/helicase to bovine SphK1 (Yamane et al., 2009).  296 
In contrast, we show that expression of DENV-2-NS3 in mammalian cells did not affect SphK1 297 
activity, consistent with findings seen with HCV NS3, a Hepacivirus of the Flaviviridae family 298 
(Yamane et al., 2009).  SphK1 activity, however, was reduced by expression of the 3’UTR region of 299 
DENV-2 RNA.  Consistent with this, 3’UTR RNA levels are high later in DENV-2-infection; the time 300 
frame over which we observe reduced SphK1 activity in DENV-2 infected cells.  eEF1A is known to 301 
bind to the WNV 3’UTR SL region and promote viral replication (Blackwell & Brinton, 1997) and to 302 
co-localise with DENV NS3/NS5 (Davis et al., 2007).  We have shown that eEF1A also binds to 303 
SphK1 and enhances the catalytic activity of this enzyme (Leclercq et al., 2008).  We have extended 304 
these studies to show that eEF1A protein levels are not altered in DENV-2 infected cells but that 305 
eEF1A co-localises to sites of DENV-2 dsRNA and co-precipitates with DENV-2 RNA.  We thus 306 
propose that the high levels of 3’UTR RNA in DENV-2 infected cells competes with SphK1 for 307 
binding to eEF1A resulting in less available eEF1A to stimulate SphK1.  We have further investigated 308 
the 3’UTR, eEF1A and SphK1 interaction using recombinant proteins and in vitro transcribed 3’UTR 309 
RNA.  Results support the ability of the DENV-2 3’UTR to prevent eEF1A-stimulated SphK1 310 
activity, Fig S2.  Our on-going research aims to further define this interaction using phosphorylated 311 
eEF1A (Blackwell & Brinton, 1997) and 3’UTR mutants that lack the ability to bind eEF1A (Davis et 312 
al., 2007). 313 
 314 
Interestingly, although our data suggests the potential for a competitive interaction between the 315 
3’UTR and SphK1 for binding eEF1A we also show that inducing changes in SphK1 activity after an 316 
established infection had no effect on infectious DENV-2 production.  Similarly, overexpression of 317 
SphK1 did not effect BVDV infection, although in contrast to our observations in DENV-infected 318 
cells, a reduction in SphK1 activity by SKi treatment enhanced BVDV RNA replication (Yamane et 319 
al., 2009).  Furthermore, in our study overexpression of a dominant negative mutant SphK1G82D which 320 
inhibits the activation of endogenous SphK1, still did not significantly affect infectious DENV-2 321 
production.  The specific details of the biochemical competition between SphK1 and the 3’UTR RNA 322 
for eEF1A remain to be investigated but factors such as the cellular co-localisation of DENV-2 RNA, 323 
eEF1A and SphK1, the high levels of DENV-2 RNA and the relative affinity of DENV-2 RNA for 324 
eEF1A compared with SphK1, may all favour the 3’UTR/eEF1A interaction in an infected cell.  It has 325 
been previously shown that DENV capsid (C) protein interacts with and degrades host cell Sec3 326 
protein, also an eEF1A binding protein (Bhuvanakantham et al., 2010).  Disruption of the SEC3-327 
eEF1A interaction by DENV-C provides an active mechanism to release cellular eEF1A and thus 328 
promote DENV-2 replication.  Our studies provide a contrasting example whereby DENV-2 RNA 329 
may sequester eEF1A at the detriment of the host cell eEF1A interacting protein, SphK1 and together 330 
these findings highlight the importance of cellular eEF1A to DENV replication.  Recently, eEF1A has 331 
been identified as a host cell component of the HIV reverse transcription complex (RTC) (Warren et 332 
al., 2012) suggesting broader roles for eEF1A in viral replication as recently reviewed (Li et al., 333 
2013). 334 
 335 
In conclusion, we have demonstrated that changes in SphK1 activity after infection do not affect 336 
DENV-2 but the reduced SphK1 activity in DENV-2-infected cells can enhance DENV-2 induced cell 337 
death.  The reduction in SphK1 activity in DENV-2 infected cells can be mediated by the 3’UTR 338 
RNA and we propose that high levels of 3’UTR RNA accumulate late in infection and competitively 339 
bind the SphK1 activator eEF1A resulting in less eEF1A-activated SphK1.  These results provide a 340 
new and novel role for the DENV-2 3’UTR in affecting SphK1 activity that has the potential to 341 
influence important cell death, cell signalling and lipid changes in infected cells. 342 
 343 
MATERIALS AND METHODS 344 
Cells and virus. Monocytes were generated by adherence of peripheral blood mononuclear cells 345 
(PBMC) isolated from blood from healthy donors taken with consent at the Australian Red Cross 346 
Blood Service and used in accordance with approval from the Southern Health Human Ethics 347 
Committee.  Monocytes were cultured to differentiate into macrophages to generate monocyte-348 
derived macrophages (MDM) and DENV-2-infected as previously described (Pryor et al., 2001; Wati 349 
et al., 2007).  Infections utilised Mon601, a clone of DENV-2 New Guinea C (Gualano et al., 1998) 350 
and virus was produced from in vitro transcribed RNA transfected into BHK-21, amplified in C6/36 351 
and titred in Vero cells.  HEK-293 cells containing doxycycline (DOX)-inducible expression of wild 352 
type SphK1, a dominant negative mutant of SphK1 (SphK1G82D) (Pitson et al., 2000) and control 353 
vector only cells were generated as previously described (Pham et al., 2008; Pitson et al., 2000). 354 
 355 
DENV-2 infection and plaque assay.  Cells were infected at a multiplicity of infection (MOI) of 1 356 
(HEK-293) or 3 (MDM) or as indicated, for 90 mins at 37oC, as described previously (Pryor et al., 357 
2001).  In some experiments cells were treated with 5µM of the SphK1 inhibitor 1-(p-hydroxyanilo)-358 
4-(p-chlorophenylthiazole) (SKi) or DMSO vehicle control.  At the indicated time points post-359 
infection (pi) supernatants were collected clarified by centrifugation and snap frozen at -80oC.  Plaque 360 
assays were performed in Vero cells and infectious virus quantitated as plaque forming units per ml 361 
(pfu/ml). 362 
 363 
DNA constructs and transfection of cells.  The terminal 396 bases of the 3’UTR was PCR amplified 364 
using primers 5’-CTATGCTAAGCTTGAGCCCCGTC-3’ and 5’-365 
CGGATCCTCTAGAACCTGTTG-3, digested with HindIII/BamHI and cloned into pBluescript KS(-366 
) to generate in vitro transcripts (pBS-WT-3’UTR) and pEGFP-C1, for expression of RNA in 367 
mammalian cells (pEGFP-WT-3’UTR).  The DENV-2 NS3 expression construct (pEPI-GFP-NS3) 368 
was generated and kindly donated by Drs Stephen Rawlinson and Professor David Jans (Monash 369 
University, Australia). 370 
 371 
HEK-293 cells were transfected with 1µg of GFP control vector, GFP-NS3 or GFP-3’UTR using 372 
polyfect (Qiagen) as per manufacturer’s instructions.  Transfected cells were incubated overnight in 373 
0.1% FCS then at 24h pi, GFP expression was visualised by fluorescent microscopy and cells were 374 
lysed and analysed for SphK1 activity, as below.  For 3’UTR expressing constructs, RNA was also 375 
extracted and analysed by RT-PCR for 3’UTR RNA, as described below. 376 
 377 
RNA extraction and RT-PCR.  At 30h pi mock and DENV-infected cells were lysed and total RNA 378 
extracted (TRIzol, Life Technologies).  To quantitate SphK1 mRNA, 1 µg of total RNA was 379 
subjected to qRT-PCR for SphK1 and results normalised against 18S rRNA.  Quantitation of 3’UTR 380 
RNA in DENV-infected or transfected cell lysates was performed by RT-PCR with primers as 381 
described for 3’UTR cloning.  Results were normalised against cellular ribosomal protein large PO 382 
(RPLPO) as described previously (Helbig et al., 2005).  Reactions were performed using Mu-MLV 383 
Reverse transcriptase and Bio-Rad IQ Sybergreen mix. PCR was performed in a real time format 384 
using a Rotorgene 6000 (Corbett Research).  In vitro transcribed 3’UTR RNA was used as standards 385 
in RT-PCR reactions and was generated by linearization ofpBS-3’UTR constructs with HindIII and in 386 
vitro transcription with T3 polymerase.  Transcribed RNA was DNAse treated, purified and 387 
quantitated (NanoDrop 1000 spectrophotometer, Thermo Scientific). 388 
 389 
SphK1 activity assays.  Cells were lysed in 100mM Tris pH 7.4, 10mM MgCl2, 1mM Na3VO4, 10mM 390 
NaF, 10% (v/v) glycerol, 100mM β-glycerophosphate, 0.05% (v/v) Triton X-100, and protease 391 
inhibitors (Roche, Complete mini).  Lysates were sonicated and total protein concentration quantitated 392 
(Bio-Rad protein assay).  Protein content was normalised and SphK1 activity determined by 393 
[γ32P]ATP transfer to D-erythro-sphingosine under conditions (0.3% (v/v) Triton X-100) where 394 
SphK2 activity is inhibited, as described previously (Pitman et al., 2012).  SphK1 activity was also 395 
analysed in vitro using 0.5 ng of recombinant human SphK1 (rSphK1), generated in E. coli as 396 
described previously (Leclercq et al., 2008; Pitson et al., 2002). 397 
 398 
Immunoprecipitation of eEF1A.  HeLa were DENV-2 infected, as above, and at 30h pi cells were 399 
lysed (50mM Tris-HCl, 100 mMNaCl, 1mM EDTA, 1% [v/v] Triton X-100, pH 7.4 with protease 400 
inhibitors (Roche, Complete mini) for 1 h at 4oC.  Lysates were clarified by centrifugation (10,000 xg, 401 
10min, 4oC) and incubated with 1 μg of eEF1A or control antibody (mouse anti-eEF1A, clone CBP-402 
KK1, #05-235, Millipore).  Complexes were captured with protein A-sepharose, washed 6 times 403 
(50mM Tris-HCl, 100 mMNaCl, 1mM EDTA, 0.1% [v/v] Triton X-100, pH 7.4) and pellets 404 
resuspended in water.  Co-precipitated DENV-2 RNA was analysed by real time RT-PCR, using 405 
primers DENV3.2 and DENV5.1 targeted against the DENV-2 C region, as previously described 406 
(Wati et al., 2007). 407 
 408 
Immunostaining and confocal microscopy.  Cells were grown on gelatin coated glass coverslips, fixed 409 
in 1% (v/v) formaldehyde and stored at -20oC. Slides were washed in PBS, permeabilised with 0.05% 410 
(v/v) IGEPAL and blocked in 4% (v/v) goat serum, 5% (v/v) FCS, 0.4% (w/v) bovine serum albumin 411 
(BSA) in PBS.  For staining of MDM, cells were blocked as above but FCS was substituted with 2% 412 
(v/v) human serum.  Cells were stained using mouse anti-DENV-2 (serotypes 1-4, Santa Cruz 413 
Biotechnology Inc, 1/100 dilution) and rabbit anti-SphK1 (Cell Signalling, #3297, 1/200) or mouse 414 
anti-dsRNA (English and Scientific Consulting, J2, 1/200) and rabbit anti-eEF1A (Cell Signalling, 415 
#2551, 1/25).  Complexes were detected with goat anti-mouse IgG-Alexa 488 and goat anti-rabbit 416 
IgG-Alexa 647 (Molecular Probes) secondary antibodies and nuclei were stained with Hoechst.  417 
Fluorescence was visualised by confocal microscopy (Biorad Radiance 2100 or Leica Sp5 Spectral 418 
Confocal Microscope). 419 
 420 
Western blot analysis.  30µg of total protein was subjected to SDS-PAGE and western blot.  Filters 421 
were probed for SphK1 (Cell Signalling, #3297, 1/1000) and eEF1A (Cell Signalling, #2551, 1/1000) 422 
with detection of proteins with goat anti-rabbit and goat anti-mouse IgG-HRP conjugate, respectively.  423 
Bound complexes were visualised by chemiluminesence and images captured (LAS 4000, Fuji 424 
Imaging systems).  Filters were re-probed for actin (Chemicon International, MAB1501R, 1/1000), 425 
with detection as above. 426 
 427 
Quantitation of cell viability.  HEK-293 cells were cultured in 96 well plates, DENV-2 infected and 428 
treated ± SKi.  At the indicated time point pi, supernatant was removed and cells fixed with 0.2% 429 
(w/v) crystal violet in 20% (v/v) methanol for 15 mins at room temperature.  Stain was removed and 430 
cells washed in water.  Bound stain was solubilsed in 1% (w/v) SDS for 60 mins and absorbance at 431 
520 nm measured. 432 
 433 
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 610 
FIGURE LEGENDS 611 
FIGURE 1. Increased SphK1 activity does not affect DENV-2 infection.  HEK293 cells with 612 
DOX-inducible SphK1, SphK1G82Dor vector control were mock or DENV-2-infected then treated with 613 
DOX at 1ng/ml.  A. At 24h pi cells were lysed and SphK1 activity assayed.  B. At the indicated time 614 
point pi supernatant was collected and analysed for infectious virus release.  Results represent 615 
cumulative virus titre, mean ± SEM, (n=4). Results in A and B were from the same experiment. C.  At 616 
24h pi cells were lysed and SphK1 protein detected by western blot with normalisation against actin.  617 
D. At 48h pi supernatant was collected and analysed for infectious virus release.  Results represent 618 
cumulative virus titre, mean ± SEM, (n=3). Results shown in C and D were from the same 619 
experiment. 620 
 621 
FIGURE 2. Inhibition of SphK1 activity does not affect DENV-2 infection.  HEK293 cells were 622 
DENV-infected and treated with 5µM SKi or vehicle (DMSO).  At the indicated time point pi A. cells 623 
were lysed and SphK1 activity assayed.  Results represent mean ± SEM (n=3), p<0.05, Students t-test, 624 
SphK1 activity is normalised per µg of total protein and expressed relative to mock infected control.; 625 
B. supernatants were collected and analysed for infectious virus release.  Results represent cumulative 626 
virus titre; C. MDM were isolated, DENV-2-infected, treated with 5µM SKi or vehicle and 627 
supernatant sampled at 48h pi and analysed for infectious virus release. 628 
 629 
FIGURE 3. SKi treatment of DENV-2 infected cells reduces cell viability.  HEK293 cells were 630 
mock or DENV-infected and treated with vehicle (DMSO) (A) or 5µM SKi (B).  At the indicated time 631 
point pi cells were lysed and SphK1 activity assayed.  Results represent mean ± SEM (n=2), * = 632 
p<0.05, Students t-test, SphK1 activity is normalised per µg of total protein and expressed relative to 633 
mock infected control.; C. cells were fixed, stained with crystal violet and absorbance at 520 nm 634 
quantitated. Results represent mean ± SEM (n=5), * = p<0.05, Students t-test. 635 
 636 
FIGURE 4. Reduced SphK1 activity in DENV-2 infected cells is not associated with DENV-2-637 
induced CPE.  Cells were mock or DENV-2-infected.  Prior to collection of samples for SphK1 638 
activity quantitation, cells were incubated overnight in 0.1% FCS containing media.  At 30h pi 639 
(C6/36, BHK-21, HEK-293) or 48h pi (K562) cells were lysed and SphK1 activity assayed.  Results 640 
represent mean ± SEM, (n=4).  MDM were isolated from blood and mock or DENV-2-infected.  At 641 
24h pi cells were treated with 0.5ug/ml TNF-α antibody then at 48h pi cells were lysed and SphK1 642 
activity assayed.  Results represent mean ± SEM, (n=3). *= p<0.05, Students t-test.  SphK1 activity is 643 
normalised per µg of total protein and expressed relative to mock infected control. 644 
 645 
FIGURE 5. DENV-2 reduction in SphK1 activity is mediated post-translationally.  A. HEK-293 646 
cells were mock or DENV-2 infected and at 30h pi cells lysed and 30 µg of lysate analysed by 647 
western blot for SphK1 with normalisation by re-probing for actin. B.  MDM were isolated from 648 
blood and mock or DENV-2-infected.  At 48h pi cells were fixed and immunostained for DENV E-649 
antigen (mouse D1-11, Santa Cruz Biotechnology, 1/150 dilution) and SphK1 (rabbit, anti-SphK1, 650 
Cell Signalling, #3297, 1/200), with detection of complexes with Alexa 488 and 647 conjugated 651 
antibodies, respectively and visualisation by confocal microscopy.  Nuclei were visualised by Hoechst 652 
staining. C. HEK-293 cells were mock or DENV-2-infected and at 30h pi lysed, total RNA extracted 653 
and subjected to qPCR for SphK1 mRNA.  Results are expressed as fold change relative to 18SrRNA.  654 
Results represent mean ± SEM, (n=3); D. 0.5 ng of rSphK1 was incubated with 20 µg of total protein 655 
from mock or DENV-2-infected cells for 15 mins, prior to analysis of SphK1 activity. Results are 656 
normalised relative to the activity of rSphK1 alone and represent mean ± SEM, (n=4), *= p<0.05, 657 
Students t-test. 658 
 659 
FIGURE 6. Inhibition of SphK1 activity is mediated by the DENV-2 3’UTR.  HEK-293 cells 660 
were transfected to express A. GFP control or GFP-NS3 or B. GFP control or GFP-3’UTR.  At 24h 661 
post transfection cells were lysed and SphK1 activity assayed, SphK1 activity is normalised per µg of 662 
total protein and expressed relative to GFP-transfected control.. Results represent mean ± SEM, (n=5), 663 
* = p<0.05, Students t-test. 664 
 665 
FIGURE 7. The reduction in SphK1 activity correlates with high levels of the DENV-2 3’UTR 666 
RNA.  HEK293 cells were DENV-2 or mock-infected. Prior to collection of samples cells were 667 
incubated overnight in 0.1% FCS containing media then samples collected at the indicated time points 668 
pi. A. SphK1 activity was quantitated in cell lysates, SphK1 activity is normalised per µg of total 669 
protein and expressed relative to mock infected control; B. infectious virus production was analysed 670 
in culture supernatant by plaque assay.  Results represent mean ± SEM from one of three independent 671 
experiments. * p<0.05, Students t-test. C. RNA was extracted from DENV-2 infected HEK293 cells 672 
and 3’UTR RNA was quantitated by qRT-PCR and normalised for cellular RPLPO. 673 
 674 
FIGURE 8.  eEF1A protein is unaltered in DENV-2 infected cells, localises to dsRNA and binds 675 
to DENV-2 RNA.  HEK-293 cells were mock or DENV-2 infected and at 30h pi cells A. lysed and 30 676 
µg of lysate analysed by western blot for eEF1A and actin; B. fixed and immunostained for dsRNA 677 
(mouse anti-dsRNA, English and Scientific Consulting, J2, 1/200), and eEF1A (rabbit anti-eEF1A, 678 
Cell Signalling, 1/25 dilution) with detection of complexes with Alexa 488 and 647 conjugated 679 
antibodies, respectively and visualisation by confocal microscopy.  Nuclei were visualised by Hoechst 680 
staining; C. lysed and incubated with eEF1A or control antibody.  Immunoglobulin complexes were 681 
precipitated with protein-A sepharose, washed and analysed for DENV-2 RNA by qRT-PCR.  Results 682 
are expressed as copy number precipitated per equivalent ml of cell lysate (n=6, from 3 independent 683 
precipitations, p<0.05). 684 








